Clinical Trial Update: Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating XELOXIRI (capecitabine, oxaliplatin, and irinotecan) as first-line therapy in patients with advanced unresectable pancreatic adenocarci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• Camptosar (irinotecan)
• Eloxatin (oxaliplatin)
• Xeloda (capecitabine)

Snippet

Sponsor: The University of Hong Kong | Conditions: Pancreatic Adenocarcinoma | Phase 2 | Status: COMPLETED